Therapeutic compositions and methods for treating HIV including identification and manipulation of particular domains associated with immunogenicity

Patent metadata

Field	Value
Publication number	US-10201603-B2
Application number	US-201715694388-A
Country	US
Kind code	B2
Filing date	Sep 1, 2017
Priority date	Oct 4, 2008
Publication date	Feb 12, 2019
Grant date	Feb 12, 2019

Abstract

Selection of HIV vaccine antigens by use of intrapatient sequence variation to identify mutations in the HIV envelope glycoprotein that affect the binding of broadly neutralizing antibodies and polypeptides identified by these methods.

First claim

The invention claimed is:

1. A composition comprising:
a HIV-1 gp120/gp41 trimer complex comprising a single amino acid substitution in a helix of gp41,
wherein the helix is selected from the group consisting of N36 helix and C34 helix,
wherein the single amino acid substitution is introduced at V551, Q553, or Q655, where the substituting amino acid at Q655 and Q553 is not N and the substituting amino acid at V551 is not Q or N, and
wherein the numbering of the substituted amino acid is with reference to the amino acid sequence set forth in SEQ ID NO:16.

2. The composition of claim 1 , comprising an adjuvant.

3. The composition of claim 1 , comprising an excipient.

4. The composition of claim 1 , wherein the single amino acid substitution is Q655R.

5. A method of inducing an immune response to HIV-1 in a subject, the method comprising administering the composition of claim 1 to the subject.

6. A method of inducing an immune response to HIV-1, the method comprising administering a formulation comprising an HIV envelope glycoprotein polypeptide comprising a single amino acid substitution in a helix of the HIV envelope glycoprotein polypeptide, wherein the helix is selected from the group consisting of the N36 helix and the C34 helix, wherein said single amino acid substitution increases the ability of said polypeptide to bind neutralizing antibodies, wherein the single amino acid substitution is selected from the group consisting of V551[*], Q553[*], and Q655[*], where [*] represents any amino acid other than Q or N, and wherein the numbering of the substituted amino acid is with reference to the amino acid sequence set forth in SEQ ID NO: 16.

7. The method of claim 6 , wherein the formulation comprises an excipient.

8. The method of claim 6 , wherein the formulation comprises a carrier or an adjuvant.

9. The method of claim 6 , wherein the single amino acid substitution is Q655[*], where [*] represents any amino acid other than Q or N.

10. The method of claim 6 , wherein the single amino acid substitution is Q655R.

Assignees

• Univ California

Inventors

• Berman Phillip
• O'Rourke Sara
• Scott William

Classifications

• C12N2740/16134

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title

• A61P31/18

  for HIV · CPC title

• C12N2740/15022

  New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes · CPC title

• A61K39/21 Primary

  Retroviridae, e.g. equine infectious anemia virus · CPC title

• A61K38/162

  from virus · CPC title